Press "Enter" to skip to content

Pharma stocks could see turbulence from U.S. Senate drug-price hearing

U.S. healthcare stocks could face more turbulence on Tuesday, after a bumpy early 2019, as top executives from some of the largest pharmaceutical companies are expected to get grilled in the U.S. Senate on the high cost of prescription drugs.

Original source:

Also Read:   Desi drug brings cheer to patients of a rare disease